| Literature DB >> 34154603 |
Vilton Emanoel Lopes de Moura E Silva1, Jason Michael Cholewa2, Ralf Jäger3, Nelo Eidy Zanchi4, Marcelo Conrado de Freitas5, Rayane Carvalho de Moura1, Esmeralda Maria Lustosa Barros6, Barbara Moura Antunes7, Erico Chagas Caperuto8, Sergio Luiz Galan Ribeiro1, Fabio Santos Lira7, Marcos Antônio Pereira Dos Santos6, Fabrício Eduardo Rossi9,10.
Abstract
BACKGROUND: Acute capsaicinoid and capsinoid supplementation has endurance and resistance exercise benefits; however, if these short-term performance benefits translate into chronic benefits when combined with resistance training is currently unknown. This study investigated changes of chronic Capsiate supplementation on muscular adaptations, inflammatory response and performance in untrained men.Entities:
Keywords: Hypertrophy; Performance; Pre-workout; Strength training
Year: 2021 PMID: 34154603 PMCID: PMC8218493 DOI: 10.1186/s12970-021-00446-0
Source DB: PubMed Journal: J Int Soc Sports Nutr ISSN: 1550-2783 Impact factor: 5.150
Fig. 1Experimental design
Comparison between Capsiate supplementation and placebo groups on the body compositionand performance. Data are presented as mean +/- SD
| Capsiate | 69.9 ± 11.9 | 70.8 ± 11.6 | 0.825 | 0.08 |
| Placebo | 68.3 ± 11.5 | 69.1 ± 11.2 | 0.07 | |
| Capsiate | 57.9 ± 7.8 | 59.2 ± 7.8 ¥ | 0.024 | 0.20 |
| Placebo | 58.7 ± 7.7 | 59.0 ± 7.2 | 0.04 | |
| Capsiate | 11.9 ± 4.9 | 11.6 ± 4.6 | 0.340 | -0.06 |
| Placebo | 9.8 ± 5.4 | 10.6 ± 5.6 | 0.15 | |
| Capsiate | 16.5 ± 5.2 | 15.9 ± 4.6 | 0.333 | -0.12 |
| Placebo | 13.9 ± 5.7 | 14.1 ± 5.9 | 0.03 | |
| Capsiate | 15.8 ± 2.2 | 16.2 ± 2.1 | 0.477 | 0.20 |
| Placebo | 15.9 ± 2.1 | 16.1 ± 2.2 | 0.09 | |
| Capsiate | 26.5 ± 3.4 | 26.9 ± 3.4 | 0.842 | 0.12 |
| Placebo | 26.7 ± 3.8 | 27.1 ± 3.6 | 0.11 | |
| Capsiate | 41.9 ± 5.4 | 42.9 ± 5.4 | 0.198 | 0.20 |
| Placebo | 42.5 ± 5.9 | 43.0 ± 5.7 | 0.09 | |
| | ||||
| Capsiate | 276.4 ± 77.1 | 380.6 ± 86.5 | 0.426 | 1.30 |
| Placebo | 292.2 ± 55.9 | 388.9 ± 56.0 | 1.70 | |
| | ||||
| Capsiate | 55.2 ± 16.6 | 61.7 ± 16.4¥ | 0.034 | 0.40 |
| Placebo | 60.6 ± 14.7 | 63.9 ± 15.1¥ | 0.22 | |
| | ||||
| Capsiate | 2793.4 ± 808.3 | 3753.1 ± 715.9 | 0.690 | 1.26 |
| Placebo | 2646.6 ± 756.9 | 3514.4 ± 1073.2 | 0.95 | |
| | ||||
| Capsiate | 2301.2 ± 636.7 | 3201.3 ± 551.7 | 0.819 | 1.51 |
| Placebo | 2003.6 ± 644.7 | 3177.6± 943.8 | 1.48 | |
ES effect size, ANCOVA Analysis of covariance used to adjust for pre-intervention
Note: ¥=Bonferroni’s Post hoc with statistically significant difference compared to Pre
Fig. 2Relative changes and individual response in the fat-free mass (a) and upper body strength (b) after 6 weeks of intervention in the Capsiate supplementation and placebo groups
Comparison of the total number of repetition for acute resistance exercise at pre and post-intevention
| Exercise | Group | Pre-intervention | After 6 weeks | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 20.6 ± 2.9 | 12.9 ± 2.1 a | 10.9 ± 1.8 a.b | 44.3 ± 5.7 | 12820.0 ± 2222.3 | 25.4 ± 4.9 | 16.3 ± 3.5 a | 11.2 ± 2.0 a.b | 53.0 ± 9.7* | 20675.0 ± 5036.7* | |||
| 22.4 ± 3.7 | 12.9 ± 3.5a | 10.1 ± 2.3 a.b | 45.4 ± 7.7 | 12429.1 ± 4085.7 | 28.6 ± 2.7 | 17.6 ± 4.8 a | 11.8 ± 1.8 a.b | 58.1 ± 8.5* | 21962.3 ± 5497.7* | |||
| 14.1 ± 3.4 | 6.2 ± 1.2 a | 2.9 ± 0.6 a.b | 23.2 ± 4.0 | 1395.9 ± 368.8 | 16.1 ± 4.9 | 8.8 ± 1.4 a | 5.4 ± 1.5 a.b | 30.3 ± 5.6* | 1912.8 ± 458.2* | |||
| 14.4 ± 3.1 | 7.0 ± 1.5 a | 3.8 ± 1.2 a.b | 25.2 ± 4.1 | 1368.6 ± 386.9 | 15.6 ± 3.0 | 8.1 ± 1.4 a | 5.1 ± 1.5 a.b | 28.8 ± 4.8* | 1787.0 ± 614.0* | |||
TWL total weight lifted, CAP Capsiate supplementation
Note: a= lower than Set-1; b= lower than Set-2. *= higher than Pre-intervention
Inflammatory response at baseline and after 6 weeks of chronic resistance training isolated and combined with Capsiate supplementation
| Variables | Pre-intervention | After 6 weeks | ||||||
|---|---|---|---|---|---|---|---|---|
| 0.27 ± 0.11 | 0.32 ± 0.16 | 0.27 ± 0.11 | 0.32 ± 0.16 | 0.27 ± 0.08 | 0.24 ± 0.07 | 0.31 ± 0.23 | 0.25 ± 0.05 | |
| 0.48 ± 0.23 | 0.58 ± 0.45* | 0.56 ± 0.27 | 0.75 ± 0.25* | 0.58 ± 0.26 | 0.51 ± 0.30* | 0.58 ± 0.22 | 0.68 ± 0.28* | |
| 0.75 ± 0.15 | 0.91 ± 0.19£ | 0.95 ± 0.25 | 1.0 ± 0.28£ | 0.96 ± 0.34 | 0.85 ± 0.42 | 1.04 ± 0.34 | 1.04 ± 0.32 | |
| 2.88 ± 0.24 | 2.93 ± 0.29 | 2.98 ± 0.25 | 3.12 ± 0.28 | 2.94 ± 0.24 | 3.03 ± 0.21 | 3.10 ± 0.25 | 3.25 ± 0.22 | |
Note: TNF-α Tumor necrosis factor-α, TNF-R Soluble tumor necrosis factor-α receptor. £= exercise × time interaction with significant difference compared to Rest. *= a main effect of exercise